Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: A multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial

The Lancet Haematology

Volumn 2, Issue 10, 2015, Pages e417-e426

  Platzbecker, Uwe ^a   Wong, Raymond S M ^b   Verma, Amit ^c   Abboud, Camille ^d   Araujo, Sergio ^e   Chiou, Tzeon Jye ^f   Feigert, John ^g   Yeh, Su Peng ^h   Götze, Katharina ⁱ   Gorin, Norbert Claude ^j   Greenberg, Peter ^k   Kambhampati, Suman ^l   Kim, Yoo Jin ^m   Lee, Je Hwan ⁿ   Lyons, Roger ^o   Ruggeri, Marco ^p   Santini, Valeria ^q   Cheng, Gregory ^r   Jang, Jun Ho ^s   Chen, Chien Yuan ^t   Johnson, Brendan ^u   Bennett, John ^v   Mannino, Frank ^u   Kamel, Yasser Mostafa ^w   Stone, Nicole ^u   Dougherty, Souria ^u   Chan, Geoffrey ^u   Giagounidis, Aristoteles ^x   more..

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j HÔPITAL SAINT ANTOINE   (France)

^k STANFORD CANCER INSTITUTE   (United States)

^l UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^m The Catholic University of Korea   (South Korea)

ⁿ Asan Medical Center   (South Korea)

^o Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^p SAN BORTOLO HOSPITAL   (Italy)

^q CAREGGI UNIVERSITY HOSPITAL   (Italy)

^r MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

^s Samsung Medical Center   (South Korea)

^t NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^u GLAXOSMITHKLINE   (United States)

^v UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^w GLAXOSMITHKLINE   (United Kingdom)

^x MARIEN HOSPITAL DÜSSELDORF   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; PLACEBO; BENZOIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ANEMIA; ARTICLE; BONE PAIN; CHROMOSOME ABERRATION; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTRITIS; HUMAN; HYPOALBUMINEMIA; INFECTION; KIDNEY FAILURE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERY ELDERLY; ADULT; AGONISTS; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BENZOATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDRAZINES; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84955489982     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00149-0     Document Type: Article

References (30)

1. van Lom K, Houtsmuller AB, van Putten WL, Slater RM, Lowenberg B. Cytogenetic clonality analysis of megakaryocytes in myelodysplastic syndrome by dual-color fluorescence in situ hybridization and confocal laser scanning microscopy. Genes Chromosomes Cancer 1999; 25: 332-38.
2. Liesveld JL, Jordan CT, Phillips GL 2nd. The hematopoietic stem cell in myelodysplasia. Stem Cells 2004; 22: 590-99.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88.
4. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380: 1309-16.
5. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007; 109: 1705-14.
6. Neukirchen J, Blum S, Kuendgen A, et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol 2009; 83: 477-82.
7. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-47.
8. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377: 393-402.
9. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 641-48.
10. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-36.
11. Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. BMC Cancer 2013; 13: 121.
12. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012; 367: 11-19.
13. Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2014; 146: 442-52.
14. Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009; 114: 3899-908.
15. Kalota A, Gewirtz AM. A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. Blood 2010; 115: 89-93.
16. Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res 2010; 34: 1224-31.
17. Mavroudi I, Pyrovolaki K, Pavlaki K, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res 2011; 35: 323-28.
18. Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 2012; 120: 386-94.
19. Prica A, Sholzberg M, Buckstein R. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. Br J Haematol 2014; 167: 626-38.
20. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974; 27: 365-75.
21. Gibiansky E, Zhang J, Williams D, et al. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 2011; 51: 842-56.
22. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-49.
23. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014; 123: 1818-25.
24. Chauncey TR, Gundacker H, Shadman M, et al. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br J Haematol 2010; 148: 48-58.
25. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-803.
26. Platzbecker U, Braulke F, Kundgen A, et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia 2013; 27: 1403-07.
27. Rusnak DW, Rudolph SK, Safavi A, Erickson-Miller CL. Eltrombopag, but not romiplostim or thrombopoietin, inhibits growth of thrombopoietin receptor positive and negative human leukemia cell lines. Blood 2012; 120: abstr 4726.
28. Oliva E, Santini V, Zini G, et al. Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: results of a prospective, randomized, trial. Haematologica 2013; 98: abstr S1110.
29. Svensson T, Garelius H, Lorenz F, Saft L, Hellstrom-Lindberg E, Cherif H. A pilot phase one dose finding safety study of a thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. Haematologica 2013; 98: abstr S595.
30. Dickinson M, Herbert K, Sardjono C, et al. High doses of eltrombopag are well-tolerated in conjunction with azacitidine and the combination demonstrates encouraging activity in patients with MDS and AML. Haematologica 2013; 98: abstr P188.